Compare Amylx Pharmaceuticals Inc (AMLX) vs Remitly Global Inc (RELY) Price & Performance

AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.

The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.

RELY trades at $23.77, up 0.89% today, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported Q1 2026 EPS of $0.23, beating expectations, and raised full-year guidance to $1.96–$1.975 billion revenue. Recent news highlights a UAE license and market share gains.

Outlook is positive with 92% analyst buy ratings and a $26.75 consensus target, but high P/E of 49.52 and competitive pressures in remittance pose risks. Profitability has turned positive, with net income reaching $67.93M in 2025 after prior losses, signaling a sustainable growth trajectory if execution continues.